gip and glp-1 agonist Dual GIP/GLP-1 receptor agonists: New advances for treating type-2 diabetes New strategies for the treatment
Description
Sharma D, Verma S, Vaidya S, Kalia K, Tiwari V
Its incidence is increasing with growing obesity rates worldwide [2], with only modest weight gain being associated with an increased risk of developing IIH or experiencing a relapse after remission [3]
doi: 10.1177/1060028017689878 64 Pharmacological profile, efficacy and safety of lixisenatide in type 2 diabetes mellitus
Long-term dipeptidyl-peptidase 4 inhibition reduces atherosclerosis and inflammation via effects on monocyte recruitment and chemotaxis
Maselli DB, Lee D, Bi D, et al
